Xpovio® (selinexor) approved for new indication in dlbcl in china, bringing a new treatment option to patients in the country

- following its initial approval for the treatment of relapsed/refractory multiple myeloma (r/r mm), xpovio® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl) marking the second approved indication of xpovio® in china. - results from the registrational search study in china showed that the overall response rate (orr) among the 60 chinese patients treated with xpovio® met the study's prespecified primary endpoint.
KPTI Ratings Summary
KPTI Quant Ranking